查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1990479

造影超音波市场：依方法、技术、应用和最终用户划分－2026-2032年全球市场预测

Contrast Enhanced Ultrasound Market by Mode, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，造影超音波市场价值将达到 23.5 亿美元，到 2026 年将成长至 24.9 亿美元，到 2032 年将达到 36.9 亿美元，复合年增长率为 6.64%。

主要市场统计数据
基准年 2025 23.5亿美元
预计年份：2026年 24.9亿美元
预测年份 2032 36.9亿美元
复合年增长率 (%) 6.64%

简洁而有策略地将对比造影超音波为一种具有临床影响力的诊断方法，它重塑了患者的治疗路径和影像诊断方面的决策。

造影超音波结合了微气泡造影造影和先进的超音波技术，是诊断影像领域的重大进步，它能够显着改善病灶显像、血管评估和即时功能评估。在过去十年间，临床医生越来越多地利用造影超音波来提高肝病学、肿瘤学、循环系统和急诊医学的诊断准确性，同时，诊断影像团队也在寻求能够减少辐射暴露并提高患者诊疗效率的影像方式。本文认为，造影超音波不仅是一项技术革新，更是一种实用的临床工具，它正在重塑急诊和门诊等各种诊疗场景下的诊断流程。

这是一个重要的技术、临床和商业性转折点，正在加速医疗保健领域的采用，并重塑实施方法。

在造影超音波领域，正在发生多项变革性变化，这些变化正在重新调整临床实践、采购和创新的优先事项。换能器设计、讯号处理和造影配方方面的进步正在提高超音波在血管表征和病变评估中的灵敏度和特异性。同时，软体分析和人工智慧影像增强技术的整合，正使影像诊断从完全依赖操作者转向更标准化的评估，从而支持不同医疗机构和临床医生之间诊断结果的可重复性。

关税政策的变化对造影超音波技术的供应链、采购决策和临床应用趋势产生了哪些影响？

近期贸易政策推出导致的新关税措施已成为采购负责人、製造企业负责人和临床营运团队必须重点考虑的问题。影响进口零件、成品超音波诊断设备和药用级造影剂的关税可能会造成下游成本压力，进而导致资本投资放缓和筹资策略的重新评估。医疗系统和影像中心目前不仅要评估各项成本，还要评估总体拥有成本 (TCO)，其中包括在贸易环境变化下的维护、培训和供应连续性等成本。

详细的細項分析揭示了模式选择、技术方法、临床适应症和最终用户特征如何影响采用管道和采购选择。

细分洞察揭示了成像模式选择、成像技术、临床应用和最终用户画像如何相互交织，共同决定部署模式和投资优先顺序。成像模式的选择会影响工作流程。例如，多普勒成像可辅助血管评估和血流定量，谐波成像可提高病灶检测中组织对比度的分离度，而即时成像则支援床边操作过程中的连续可视化。每种成像模式都有其独特的学习曲线和通讯协定要求，相关人员必须使其与临床目标和人员配置模式相协调。

区域采用趋势、全球临床实施、与报销制度的一致性以及决定供应链韧性的区域特定策略考量。

区域趋势受独特的采纳因素、监管考虑和营运重点的影响，这些因素共同作用，影响着造影超音波的普及应用。在美洲，医保报销机制、大规模综合医疗保健系统以及对床边影像的高度重视，持续推动急诊和循环系统的临床应用。对培训计画的投入以及集中式研究网络的存在，有助于在区域层面产生循证医学证据，并支持更广泛的临床应用以及整个医疗保健网络内的通讯协定标准化。

主要企业正致力于整合硬体、造影剂优化、高阶软体分析和服务主导模式，以确保临床部署的成功。

造影超音波领域的公司正着力于几个相互融合的优先事项，以保持其临床意义和商业性发展势头。产品研发的投资主要集中在改进用户工程设计、提升探头技术以提高穿透力和分辨率，以及整合先进的软体工具以实现造影剂定量和灌注成像的自动化。这些改进旨在减少操作者差异，并创建可重复的指标，以便将其纳入临床决策演算法。

制定可操作的策略重点，协调临床证据的产生、产品可用性和供应链韧性，以加速在所有医疗保健环境中的永续部署。

产业领导者应推动一系列合作倡议，将临床证据、商业化和供应链韧性相结合，以加速造影超音波的持续应用。应优先投资于多中心临床研究，以产生可靠的疗效比较证据，证明造影超音波技术与有意义的临床终点和运作效率之间的关联。加强证据基础将有助于与保险公司和临床管治委员会进行建设性对话，并促进该技术在不断变化的报销限制下获得更广泛的认可。

采用严谨的混合方法研究途径，结合对临床医师的访谈、监管审查、技术检验和证据三角检验，以确保研究结果的可靠性。

本分析的调查方法结合了严谨的定性和定量方法，以确保研究结果具有实证基础，并与临床实践密切相关。关键的定性资料包括对循环系统、放射学、肿瘤学和急诊医学领域的临床医生、医院和影像中心的采购经理以及系统整合商和造影剂生产商的技术专家进行的结构化访谈。这些访谈深入剖析了影响采纳决策的实际工作流程、训练需求和采购考量。

对增强造影的临床价值提案、操作前提条件和广泛应用面临的策略挑战进行综合分析。

造影超音波正处于一个重要的转折点，临床效用、技术成熟度和实际操作条件在此交汇融合，为改善诊断医学创造了切实的机会。该技术的优势——即时灌注成像、良好的安全性以及床边应用性——使其成为循环系统、肿瘤学、急诊医学以及更广泛的诊断流程中的辅助工具。然而，要充分发挥其潜力，需要在实证医学、教育和商业策略方面做出协调一致的努力。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按模式造影超音波市场

  • 多普勒影像
  • 谐波成像
  • 即时成像

第九章造影超音波市场：依技术划分

  • 高机械指数成像
  • 低机械指数成像

第十章造影超音波市场：依应用领域划分

  • 循环系统
  • 紧急医疗护理
  • 肿瘤学
  • 放射科

第十一章：造影超音波市场：依最终用户划分

  • 学术和研究机构
  • 门诊手术中心
  • 诊断影像中心
  • 医院

第十二章：造影超音波市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：造影超音波市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：造影超音波市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国造影超音波市场

第十六章 中国造影超音波市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bracco SpA
  • Bristol-Myers Squibb Company
  • Canon Inc.
  • Carestream Health, Inc.
  • Daiichi Sankyo Company, Limited
  • Esaote SpA,
  • FUJIFILM Corporation
  • GE HealthCare Technologies Inc.
  • Hitachi, Ltd.
  • Koninklijke Philips NV
  • Lantheus Holdings, Inc.
  • Leriva SA
  • Mayo Clinic
  • Medtronics PLC
  • Mobisante, Inc.
  • nanoPET Pharma GmbH
  • Samsung Medison Co., Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Siemens AG
  • TeraRecon, Inc.
  • Toshiba Corporation
  • Trivitron Healthcare Private Limited
Product Code: MRR-3A68B8397AEE

The Contrast Enhanced Ultrasound Market was valued at USD 2.35 billion in 2025 and is projected to grow to USD 2.49 billion in 2026, with a CAGR of 6.64%, reaching USD 3.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.35 billion
Estimated Year [2026] USD 2.49 billion
Forecast Year [2032] USD 3.69 billion
CAGR (%) 6.64%

A concise strategic framing of contrast enhanced ultrasound as a clinically impactful diagnostic modality reshaping patient pathways and imaging decision making

Contrast enhanced ultrasound represents a pivotal evolution in diagnostic imaging, combining microbubble contrast agents with advanced ultrasound modalities to enhance lesion conspicuity, vascular assessment, and real-time functional evaluation. Over the last decade, clinicians have increasingly leveraged contrast enhanced ultrasound to refine diagnostics in hepatology, oncology, cardiology, and emergency medicine, while imaging teams pursue modalities that reduce radiation exposure and streamline patient throughput. This introduction frames contrast enhanced ultrasound not merely as an incremental technology but as a practical clinical tool reshaping diagnostic pathways across acute and ambulatory settings.

The clinical appeal of contrast enhanced ultrasound stems from its safety profile, repeatability at the bedside, and the capacity to deliver dynamic perfusion information without ionizing radiation. Practitioners benefit from portable deployment and the immediacy of real-time imaging, enabling faster diagnostic decisions in emergency departments and procedural guidance in interventional suites. Concurrently, imaging departments and health systems have sought to integrate contrast protocols into standard workflows, balancing training needs with procedural efficiencies and reimbursement considerations.

As a strategic framing, this introduction emphasizes the interplay between clinical evidence generation, technology maturation, and stakeholder adoption. It sets the stage for deeper analysis of technological shifts, regulatory landscapes, procurement dynamics, and the commercial actions necessary to translate clinical potential into sustainable clinical practice.

Critical technological, clinical, and commercial inflection points that are driving widespread adoption and reshaping implementation approaches across care settings

The landscape for contrast enhanced ultrasound is undergoing several transformative shifts that recalibrate clinical practice, procurement, and innovation priorities. Advances in transducer design, signal processing, and contrast agent formulations are augmenting the sensitivity and specificity of ultrasound for vascular characterization and lesion assessment. Simultaneously, the integration of software analytics and AI-enabled image enhancement is transitioning interpretation from purely operator dependent to more standardized assessments, supporting reproducibility across institutions and clinicians.

Clinical protocols are evolving in parallel: cross-disciplinary guidelines increasingly recognize the role of contrast enhanced ultrasound in targeted applications, which fosters collaborative pathways between radiology, cardiology, oncology, and emergency medicine. This multidisciplinary adoption is encouraging clinical trials that expand indications and strengthen evidence for noninvasive diagnostic strategies. Additionally, point-of-care adoption is rising as emergency and critical care clinicians employ contrast techniques to expedite triage and therapeutic decisions, thereby reducing time to intervention in acute scenarios.

From a commercial standpoint, the market is witnessing consolidation of hardware and contrast agent strategies, with vendors focusing on platform differentiation through ease of use, automated workflows, and regulatory clarity. Supply chain resilience and strategic partnerships between imaging system manufacturers and contrast agent suppliers are becoming critical to ensure consistent clinical availability. These converging shifts underscore a rebalancing from technology novelty toward practical clinical integration and scalable adoption.

How evolving tariff policies are reshaping supply chains, procurement decisions, and clinical adoption dynamics for contrast enhanced ultrasound technologies

The imposition of new tariff measures originating from recent trade policy decisions has introduced a material consideration for procurement planners, manufacturing leaders, and clinical operations teams. Tariffs affecting imported components, finished ultrasound systems, and pharmaceutical-grade contrast agents create downstream cost pressures that can slow capital purchases and prompt reevaluation of sourcing strategies. Health systems and imaging centers are now assessing not only unit costs but also total cost of ownership, which includes maintenance, training, and supply continuity under altered trade conditions.

Operationally, providers are responding by diversifying supplier relationships, increasing inventory buffers for critical consumables, and exploring local assembly or regional distribution partnerships to mitigate tariff exposure. Some manufacturers are accelerating qualification of alternative suppliers and exploring relocation of key manufacturing steps to tariff-advantaged jurisdictions to preserve competitive pricing for end users. These shifts also influence clinical adoption timelines, as procurement committees may delay upgrades pending clearer tariff trajectories or seek financing arrangements to spread capital impact over multiple fiscal periods.

Clinically, the potential for higher per-procedure costs necessitates evidence that contrast enhanced ultrasound delivers measurable improvements in diagnostic accuracy, clinical throughput, or patient outcomes that offset incremental expense. Accordingly, groups responsible for clinical governance are intensifying comparative effectiveness studies and health economics analyses to justify continued adoption under the revised cost environment. The cumulative impact of tariff dynamics is therefore multi-dimensional, affecting supply chain architecture, capital planning, and the evidentiary case for procedure-level adoption.

Deep segmentation intelligence revealing how mode selection, technological approaches, clinical indications, and end user characteristics shape adoption pathways and procurement choices

Insight into segmentation reveals how modality choices, imaging technology, clinical applications, and end-user profiles collectively dictate adoption patterns and investment priorities. Mode selection influences operational workflows; for example, Doppler imaging techniques complement vascular assessments and flow quantification, while harmonic imaging enhances contrast-to-tissue separation for focal lesion detection, and real-time imaging supports continuous visualization during bedside procedures. Each mode presents distinct training curves and protocol requirements that stakeholders must reconcile with clinical objectives and staffing models.

Technology differentiation further shapes clinical utility and workflow efficiency. High mechanical index imaging enables targeted microbubble destruction and reperfusion assessment that can be advantageous for specific perfusion studies, whereas low mechanical index imaging supports continuous real-time contrast visualization without signal disruption, making it well suited for dynamic assessments in interventional settings. These technological choices affect equipment selection and protocol development, and they often drive vendor conversations around compatibility and software capabilities.

Application-driven priorities create clear use cases that appeal to different clinical stakeholders. Cardiology leverages contrast for enhanced endocardial border definition and myocardial perfusion assessment, while emergency medicine values rapid bedside diagnostic confirmation and trauma evaluation. Oncology benefits from tumor perfusion characterization to guide biopsy and monitor therapy response, and radiology integrates contrast enhanced ultrasound as a radiation-free adjunct for lesion characterization. End users vary in operational scale and clinical complexity; academic and research institutes emphasize protocol innovation and evidence generation, ambulatory surgical centers prioritize throughput and cost efficiency, diagnostic imaging centers focus on specialized workflows and outpatient access, and hospitals require integration across inpatient and outpatient services. Taken together, these segmentation perspectives inform product positioning, clinical engagement strategies, and training investments to maximize clinical relevance and operational feasibility.

Regional adoption dynamics and localized strategic considerations that determine clinical uptake, reimbursement alignment, and supply chain resilience across global territories

Regional dynamics present distinct adoption drivers, regulatory considerations, and operational priorities that influence the diffusion of contrast enhanced ultrasound. In the Americas, reimbursement structures, large integrated health systems, and a strong emphasis on point-of-care imaging continue to drive clinical uptake in emergency departments and cardiology services. Investment in training programs and the presence of centralized research networks foster local evidence generation, supporting broader clinical acceptance and protocol standardization across health networks.

Europe, Middle East & Africa comprise a heterogeneous landscape in which regulatory frameworks, public health priorities, and infrastructure variability result in differentiated adoption rates. Several European healthcare systems demonstrate robust integration of contrast enhanced ultrasound within hepatology and oncology pathways, while regions with constrained resources prioritize cost-effective modalities and streamlined training to expand diagnostic capacity. Cross-border collaborations and pan-regional clinical guidelines play a significant role in harmonizing practice and accelerating evidence dissemination across national boundaries.

The Asia-Pacific region is characterized by rapid capital investment in imaging infrastructure, strong private provider networks, and substantial growth in procedural volumes. Clinical demand is being driven by expanding oncology services and an increasing focus on minimally invasive diagnostics. Local manufacturing capabilities and regional supply chains also influence procurement strategies, making partnerships with regional distributors and localized service models particularly important for sustained adoption. Collectively, these regional insights highlight the need for tailored commercial approaches that align clinical evidence, reimbursement realities, and operational capabilities with local priorities.

How leading companies are converging on integrated hardware, contrast agent alignment, advanced software analytics, and service-driven models to secure clinical adoption

Companies operating in the contrast enhanced ultrasound space are focusing on several convergent priorities to sustain clinical relevance and commercial momentum. Product development investments center on enhancing user ergonomics, improving probe technology for better penetration and resolution, and integrating advanced software tools that automate contrast quantification and perfusion mapping. These capabilities aim to reduce operator variability and create reproducible metrics that can be incorporated into clinical decision algorithms.

Strategic partnerships between imaging system vendors and contrast agent developers are becoming increasingly important to ensure end-to-end compatibility and to streamline regulatory pathways. Firms are also augmenting their offerings with service models that include training curricula, accreditation support, and outcome-tracking tools to demonstrate clinical value to payers and health system purchasers. On the operational front, companies are optimizing supply chains by regionalizing distribution, qualifying multiple manufacturing partners, and offering flexible procurement arrangements such as subscription and pay-per-use models to lower the barrier to entry for cost-sensitive buyers.

Competitive differentiation is shifting from hardware features alone toward integrated solutions that combine imaging hardware, contrast agent consumables, software analytics, and clinical education. This integrated approach supports adoption by addressing clinical, operational, and financial decision criteria simultaneously, and positions companies to better respond to changing regulatory and tariff environments that affect global supply chains.

Actionable strategic priorities that align clinical evidence generation, product usability, and supply chain resilience to accelerate durable adoption across care settings

Industry leaders should pursue a coordinated set of actions that align clinical evidence, commercialization, and supply chain resilience to accelerate sustainable adoption of contrast enhanced ultrasound. Prioritize investment in multicenter clinical collaborations that generate robust comparative effectiveness evidence linking contrast enhanced ultrasound procedures to meaningful clinical endpoints and operational efficiencies. Strengthening the evidentiary base will support constructive engagements with payers and clinical governance committees, enabling broader procedural acceptance under evolving reimbursement constraints.

Simultaneously, accelerate integration of user-centric software and automated workflows that reduce operator dependency and lower training barriers. Embedding quantitative perfusion analytics and decision support directly into imaging platforms will improve reproducibility and create data assets that demonstrate value across care pathways. From a commercial and operational perspective, diversify supplier networks, regionalize critical component manufacturing, and develop flexible procurement offerings that reduce exposure to tariff volatility and capital constraints.

Finally, invest in scaled clinical education programs and credentialing pathways that equip a broader cohort of clinicians to perform contrast enhanced ultrasound safely and effectively. Partnerships with academic institutions and specialty societies can amplify adoption through guideline alignment and continuing education. By combining evidence generation, product usability enhancements, supply chain strategies, and education initiatives, industry leaders can create defensible adoption pathways that withstand policy shifts and competitive pressures.

A rigorous mixed-methods research approach integrating clinician interviews, regulatory review, technical validation, and evidence triangulation to ensure robust insights

The research methodology underpinning this analysis combined rigorous qualitative and quantitative approaches to ensure findings are evidence-based and practitioner-relevant. Primary qualitative inputs included structured interviews with clinicians across cardiology, radiology, oncology, and emergency medicine, procurement leaders in hospitals and imaging centers, and technical experts from system integrators and contrast agent manufacturers. These interviews provided rich insights into real-world workflows, training needs, and procurement considerations that shape deployment decisions.

Secondary research entailed systematic review of peer-reviewed clinical studies, regulatory guidance documents, professional society position statements, and technology white papers to triangulate clinical performance claims and safety profiles. Technical assessments of device capabilities and imaging modalities were corroborated with vendor product literature and independent bench testing reports. Data synthesis used a triangulation approach that reconciled clinician perspectives, regulatory context, and technical specifications to derive actionable insights while maintaining transparency about evidence sources and any limitations.

Quality assurance steps included cross-validation of interview findings with clinical trial outcomes, sensitivity checks for supply chain and tariff assumptions, and peer review by subject matter experts. Ethical considerations and patient safety factors were integrated throughout the methodology, ensuring that recommendations prioritize clinical benefit and operational viability.

Consolidated conclusions on the clinical value proposition, operational prerequisites, and strategic imperatives for broader adoption of contrast enhanced ultrasound

Contrast enhanced ultrasound stands at a pragmatic inflection point where clinical utility, technological maturity, and operational realities converge to create tangible opportunities for improved diagnostic care. The modality's strengths-real-time perfusion imaging, favorable safety profile, and bedside applicability-position it as a complementary tool across cardiology, oncology, emergency medicine, and broader diagnostic workflows. However, realizing its full potential requires aligned efforts across evidence generation, education, and commercial strategy.

Operationally, stakeholders must navigate policy shifts and supply chain complexities that influence procurement timelines and capital investment decisions. Clinical teams and manufacturers that collaborate on standardized protocols, reproducible quantitative measures, and accessible training pathways will be best positioned to accelerate adoption. Companies that integrate hardware, consumables, and analytics into cohesive solutions and that mitigate supply chain risk will create stronger value propositions for health systems and outpatient providers.

In conclusion, contrast enhanced ultrasound offers a clinically meaningful, low-risk imaging option that can improve diagnostic confidence and patient management when deployed with thoughtful evidence, training, and procurement strategies. The path forward is collaborative and requires sustained commitment to demonstrating clinical impact and operational feasibility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Contrast Enhanced Ultrasound Market, by Mode

  • 8.1. Doppler Imaging
  • 8.2. Harmonic Imaging
  • 8.3. Real Time Imaging

9. Contrast Enhanced Ultrasound Market, by Technology

  • 9.1. High Mechanical Index Imaging
  • 9.2. Low Mechanical Index Imaging

10. Contrast Enhanced Ultrasound Market, by Application

  • 10.1. Cardiology
  • 10.2. Emergency Medicine
  • 10.3. Oncology
  • 10.4. Radiology

11. Contrast Enhanced Ultrasound Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Diagnostic Imaging Centers
  • 11.4. Hospitals

12. Contrast Enhanced Ultrasound Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Contrast Enhanced Ultrasound Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Contrast Enhanced Ultrasound Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Contrast Enhanced Ultrasound Market

16. China Contrast Enhanced Ultrasound Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bracco S.p.A.
  • 17.6. Bristol-Myers Squibb Company
  • 17.7. Canon Inc.
  • 17.8. Carestream Health, Inc.
  • 17.9. Daiichi Sankyo Company, Limited
  • 17.10. Esaote S.p.A,
  • 17.11. FUJIFILM Corporation
  • 17.12. GE HealthCare Technologies Inc.
  • 17.13. Hitachi, Ltd.
  • 17.14. Koninklijke Philips N.V.
  • 17.15. Lantheus Holdings, Inc.
  • 17.16. Leriva SA
  • 17.17. Mayo Clinic
  • 17.18. Medtronics PLC
  • 17.19. Mobisante, Inc.
  • 17.20. nanoPET Pharma GmbH
  • 17.21. Samsung Medison Co., Ltd.
  • 17.22. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 17.23. Siemens AG
  • 17.24. TeraRecon, Inc.
  • 17.25. Toshiba Corporation
  • 17.26. Trivitron Healthcare Private Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CONTRAST ENHANCED ULTRASOUND MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY DOPPLER IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY DOPPLER IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY DOPPLER IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HARMONIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HARMONIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HARMONIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY REAL TIME IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY REAL TIME IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY REAL TIME IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HIGH MECHANICAL INDEX IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HIGH MECHANICAL INDEX IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HIGH MECHANICAL INDEX IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY LOW MECHANICAL INDEX IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY LOW MECHANICAL INDEX IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY LOW MECHANICAL INDEX IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY EMERGENCY MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY EMERGENCY MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY EMERGENCY MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY RADIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY RADIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY RADIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 73. MIDDLE EAST CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 78. AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 89. ASEAN CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GCC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GCC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 94. GCC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. GCC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. GCC CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPEAN UNION CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 104. BRICS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. G7 CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. G7 CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 109. G7 CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. G7 CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. G7 CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NATO CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NATO CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 114. NATO CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. NATO CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. NATO CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES CONTRAST ENHANCED ULTRASOUND MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 120. UNITED STATES CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. UNITED STATES CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. UNITED STATES CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 125. CHINA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. CHINA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. CHINA CONTRAST ENHANCED ULTRASOUND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)